Combination of stereotactic ablative body radiation with targeted therapies

The Lancet Oncology

Volumn 15, Issue 10, 2014, Pages

  Zeng, Jing ^a   Baik, Christina ^a   Bhatia, Shailender ^a   Mayr, Nina ^a   Rengan, Ramesh ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; PAZOPANIB; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE;

ALK GENE; ANTIANGIOGENIC THERAPY; APOPTOSIS; BLOOD VESSEL PERMEABILITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; DISEASE ASSOCIATION; DISTANT METASTASIS; DOSE RESPONSE; EGFR GENE; EML4 GENE; GENE MUTATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; PH; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; THERAPY EFFECT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; WEDGE RESECTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW UP; LUNG NEOPLASMS; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIOSURGERY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; RADIOSURGERY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84906840432     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70026-9     Document Type: Review

References (74)

1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
2. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010, 28:928-935.
3. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 2014, published online May 12, 2014. 10.1093/annonc/mdu123.
4. Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 2010, 77:1146-1150.
5. Jones L, Hoban P, Metcalfe P The use of the linear quadratic model in radiotherapy: a review. Austral Phys Eng Sci Med 2001, 24:132-146.
6. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946-1955.
7. Shibamoto Y, Otsuka S, Iwata H, Sugie C, Ogino H, Tomita N Radiobiological evaluation of the radiation dose as used in high-precision radiotherapy: effect of prolonged delivery time and applicability of the linear-quadratic model. J Rad Res 2012, 53:1-9.
8. Andisheh B, Edgren M, Belkic D, Mavroidis P, Brahme A, Lind BK A comparative analysis of radiobiological models for cell surviving fractions at high doses. Technol Cancer Res Treat 2013, 12:183-192.
9. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Rad Res 2012, 177:311-327.
10. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7 suppl 3):94-100.
11. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
12. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011, 6:2036-2043.
13. Fritz P, Kraus HJ, Muhlnickel W, et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006, 1:30.
14. Ohri N, Dicker AP, Lawrence YR Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys 2012, 83:385-393.
15. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys 2011, 81:1352-1358.
16. Timmerman R, Paulus R, Pass HI, et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 7523.
17. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiov Sur 1997, 113:37-47.
18. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584.
19. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75:77-81.
20. Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010, 78:1387-1393.
21. Trakul N, Harris JP, Le QT, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012, 7:1462-1465.
22. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012, 102:335-342.
23. Scoccianti S, Ricardi U Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol 2012, 102:168-179.
24. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14:e28-e37.
25. Corbin KS, Hellman S, Weichselbaum RR Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013, 31:1384-1390.
26. Eriksson D, Stigbrand T Radiation-induced cell death mechanisms. Tumour Biol 2010, 31:363-372.
27. Hellevik T, Martinez-Zubiaurre I Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol 2014, 4:1.
28. Chen FH, Chiang CS, Wang CC, et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Can Res 2009, 15:1721-1729.
29. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 8000.
30. Kris MG, Johnson B, Berry L Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: results from the Lung Cancer Mutation Consortium (LCMC). J Thorac Oncol 2013, 8(suppl 2):S3.
31. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002, 346:92-98.
32. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
33. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
34. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
35. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
36. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
37. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
38. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
39. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
40. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
41. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
42. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
43. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7533.
44. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
45. Ibrahim N, Yu Y, Walsh WR, Yang JL Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies. Oncol Rep 2012, 27:1303-1311.
46. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012, 32:1095-1111.
47. Billis W, Fuks Z, Kolesnick R Signaling in and regulation of ionizing radiation-induced apoptosis in endothelial cells. Recent Prog Horm Res 1998, 53:85-92.
48. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
49. Kolesnick R, Fuks Z Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
50. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001, 293:293-297.
51. Pena LA, Fuks Z, Kolesnick RN Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000, 60:321-327.
52. Truman JP, Garcia-Barros M, Kaag M, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One 2010, 5:e12310.
53. Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995, 61:732-737.
54. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002, 62:1702-1706.
55. Milosevic MF, Fyles AW, Wong R, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 1998, 82:2418-2426.
56. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
57. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001, 61:2413-2419.
58. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009, 69:2514-2522.
59. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013, 73:2943-2948.
60. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
61. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
62. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
63. Gan GN, Weickhardt AJ, Scheier B, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 2014, 88:892-898.
64. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thor Oncol 2013, 8:346-351.
65. Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013, 79:33-39.
66. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010, 76:824-830.
67. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28:43-48.
68. Basille D, Andrejak M, Bentayeb H, et al. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann Pharmacother 2010, 44:383-386.
69. Yuasa T, Kitsukawa S, Sukegawa G, et al. Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer 2013, 13:3.
70. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006, 64:1295-1298.
71. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008, 26:2405-2406.
72. Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013, 85:1312-1318.
73. Goyal S, Rao MS, Khan A, Huzzy L, Green C, Haffty BG Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys 2011, 79:408-413.
74. Beal K, Abrey LE, Gutin PH Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6:2.